Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Systematic Literature Review and Network Meta-Analysis of Treatments for Relapsed/Refractory Multiple Myeloma Patients

Chrissy H. Y. Van Beurden-Tan, MSc, Margreet Franken, PhD, Hedwig Blommestein, PhD, Carin A. Uyl-De Groot, PhD, Pieter Sonneveld, MD PhD

Blood (2016) 128 (22): 2144.

https://doi.org/10.1182/blood.V128.22.2144.2144

Published: 2016

Journal Articles

Social Network Analysis (SNA) of Salvage Therapies in Multiple Myeloma (MM)

Helen Mahony, MPH, Athanasios Tsalatsanis, PhD, Rahul Mhaskar, MPH, PhD, Ambuj Kumar, MD, MPH, Benjamin Djulbegovic, MD, PhD

Blood (2012) 120 (21): 4239.

https://doi.org/10.1182/blood.V120.21.4239.4239

Published: 2012

Journal Articles

Decitabine Is Effective In Patients with Myelodysplastic Syndromes Who Failed Prior Intensive Regimen: No Negative Impact of Prior Therapy

Elias Jabbour, MD, Hagop Kantarjian, MD, Tapan Kadia, MD, Gautam Borthakur, MD, Jorge E. Cortes, A. Megan Cornelison, MSPA, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD

Blood (2010) 116 (21): 2936.

https://doi.org/10.1182/blood.V116.21.2936.2936

Published: 2010

Journal Articles

5-Year Follow-up of Patients with Relapsed/Refractory CLL Treated with Standard Chemotherapy with or without Oblimersen in Randomized Phase III Trial: Prognostic Factors and Predictive Factors for Treatment Effect

Susan O’Brien, M.D., Jane Wu, PhD, Steven Novick, MD, PhD, Kanti R. Rai, MD

Blood (2008) 112 (11): 4201.

https://doi.org/10.1182/blood.V112.11.4201.4201

Published: 2008

Journal Articles

Oblimersen (OBL; Genasense®), a Phosphorothioate (PS) Bcl-2 Antisense Oliogonucleotide (ASO), Can Be Safely Administered by Bolus Subcutaneous (SC) Injection and Brief IV Infusion.

Anthony Tolcher, Thomas Julian, Anila Qureshi

Blood (2007) 110 (11): 4724.

https://doi.org/10.1182/blood.V110.11.4724.4724

Published: 2007

Journal Articles

Addition of Oblimersen (Bcl-2 Antisense) to Fludarabine/Cyclophosphamide for Relapsed/Refractory Chronic Lymphocytic Leukemia Extends Survival in Patients Who Achieve CR/nPR: Results from a Randomized Phase 3 Study.

Susan O’Brien, Joseph Moore, Lily Ding, Steven Novick, Kanti Rai

Blood (2007) 110 (11): 751.

https://doi.org/10.1182/blood.V110.11.751.751

Published: 2007

Journal Articles

Waldenström macroglobulinemia

Arun Vijay, Morie A. Gertz

Blood (2007) 109 (12): 5096–5103.

https://doi.org/10.1182/blood-2006-11-055012

Published: 2007

Journal Articles

“Complete” Remission in Chronic Lymphocytic Leukemia (CLL) Is Strongly Affected by the Use of CT Scanning: Results from a Prospective Randomized Trial of Fludarabine Plus Cyclophosphamide (Flu/Cy) with or without Genasense (Oblimersen) in Patients with Relapsed or Refractory Disease.

Peter Maslak, MD, James Caravelli, MD, Asher Alban Chanan-Khan, MD

Blood (2006) 108 (11): 2834.

https://doi.org/10.1182/blood.V108.11.2834.2834

Published: 2006

Journal Articles

Durable Clinical Benefit Is Associated with Objective Response and Not Lack of Progression in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Results from the Genasense/Flu/Cy Phase 3 Study.

Joseph O. Moore, MD, Thomas E. Boyd, MD, Asher A. Chanan-Khan, MD, Susan O’Brien, MD

Blood (2006) 108 (11): 2828.

https://doi.org/10.1182/blood.V108.11.2828.2828

Published: 2006

Journal Articles

Feasibility of Administering Oblimersen (G3139; Genasense) with Imatinib Mesylate in Patients with Imatinib Resistant Chronic Myeloid Leukemia (CML) - Cancer and Leukemia Group B Study 10107.

Meir Wetzler, MD, Daohai Yu, PhD, Olatoyosi Odenike, MD, Eric J. Feldman, MD, David D. Hurd, MD, Eva Hoke, Vera Hars, Richard A. Larson, MD

Blood (2005) 106 (11): 1097.

https://doi.org/10.1182/blood.V106.11.1097.1097

Published: 2005

Journal Articles

Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.

Blanche Mavromatis, MD, Kanti R. Rai, MD, Paul K. Wallace, PhD, Claudia Soho, OCN, Beverly Landrigan, RN, Patricia Meyn, RN, Tracey Wei, MS, Kenneth K. Chan, PhD, Philomena Casey, MS, Steven C. Novick, MD, PhD, Asher A. Chanan-Khan, MD

Blood (2005) 106 (11): 2129.

https://doi.org/10.1182/blood.V106.11.2129.2129

Published: 2005

Journal Articles

SPC2996 - A New Bcl-2 Inhibitor for the Treatment of CLL.

Phil Kearney, PhD, Majken Westergaard, PhD, Jens Bo Hansen, Henrik F. Hansen, PhD, Charlotte A. Thrue, Miriam Frieden, PhD, Troels Koch, PhD, Henrik Ørum, PhD

Blood (2005) 106 (11): 2984.

https://doi.org/10.1182/blood.V106.11.2984.2984

Published: 2005

Journal Articles

Pre-Clinical In Vitro Evaluation of BCL-2 Antisense Compound Genasense TM (G3139; Genta, Inc.) as a Targeted Pro-Apoptotic Agent for Leukemias with t(4;11)(q21;q23) Translocations.

Blaine W. Robinson, PhD, Kathyrn C. Behling, MD, PhD, Jeffrey S. Barrett, PhD, Manish Gupta, PhD, Jessicca M. Rege, PhD, Jonni S. Moore, PhD, Andrew D. Bantly, Junhyong Kim, PhD, George Hii, Cheryl L. Willman, MD, Jeffrey Potter, Peter C. Adamson, MD, Carolyn A. Felix, MD

Blood (2005) 106 (11): 3360.

https://doi.org/10.1182/blood.V106.11.3360.3360

Published: 2005

Journal Articles

siRNA Versus Antisense Locked Nucleic Acids: Stay Single!.

Phil Kearney, PhD, Majken Westergaard, PhD, Henrik F. Hansen, PhD, Ellen M. Staarup, PhD, Troels Koch, PhD, Henrik Ørum, PhD, Jens Bo Hansen

Blood (2005) 106 (11): 614.

https://doi.org/10.1182/blood.V106.11.614.614

Published: 2005

Journal Articles

A Pilot Study of Genasense® (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.

Asher Alban Chanan-Khan, MD, Blanche Mavromatis, MD, Kanti R. Rai, MD, Philomena Casey, Steven Novick, MD, Loretta M. Itri, MD

Blood (2004) 104 (11): 4827.

https://doi.org/10.1182/blood.V104.11.4827.4827

Published: 2004

Journal Articles

Combined Targeting of the Proteasome and Bcl-2 Sensitizes Human B-Cell Lymphoma and Multiple Myeloma to Cyclophosphamide in In Vitro and In Vivo Models of These Diseases.

Owen O’Connor, MD, PhD, Lorraine Toner, Emily Smith, Sridhar Srinivasan, Francisco Hernandez, Mark Rolf, MD, Stanley Frankel, MD, Asher Chanan-Khan, MD

Blood (2004) 104 (11): 2484.

https://doi.org/10.1182/blood.V104.11.2484.2484

Published: 2004

Journal Articles

Phase II Trial of Oblimersen Sodium (G3139), Dexamethasone (Dex) and Thalidomide (Thal) in Relapsed Multiple Myeloma Patients (Pts).

Ashrof Z. Badros, MD, Olga Goloubeva, PhD, Bashi Ratterree, RN, Sabrina Natt, RN, Aaron Rapoport, MD, Javier Bolaños-Meade, MD, Ben Zhang, PhD, Jerry Zeldis, MD, PhD, Stanley Frankel, MD, Barry Meisenberg, MD, James Zwiebel, MD, J. Flaws, PhD, D. Tomic, PhD, Robert Fenton, MD, PhD

Blood (2004) 104 (11): 2400.

https://doi.org/10.1182/blood.V104.11.2400.2400

Published: 2004

Journal Articles

A Phase I Trial of Oblimersen Sodium (G3139) for Relapsed or Refractory Waldenstrom Macroglobulinemia.

Morie Abraham Gertz, MD, Susan M. Geyer, PhD, Brad S. Kahl, MD, Ashraf Badros, MD, Craig Reeder, MD, Charles Erlichman, MD

Blood (2004) 104 (11): 2407.

https://doi.org/10.1182/blood.V104.11.2407.2407

Published: 2004

Journal Articles

Phase 3 Randomized Trial of Fludarabine/Cyclophosphamide Chemotherapy with or without Oblimersen Sodium (Bcl-2 Antisense; Genasense; G3139) for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Kanti R. Rai, MD, Joseph O. Moore, MD, Thomas E. Boyd, MD, Loree M. Larratt, MD, Anatoliy K. Golenkov, MD, Benjamin Koziner, MD, Asher Chanan-Khan, MD, R. G. Bociek, MD, Loretta M. Itri, MD

Blood (2004) 104 (11): 338.

https://doi.org/10.1182/blood.V104.11.338.338

Published: 2004

Journal Articles

Phase 2 Study of Oblimersen Sodium (G3139; Bcl-2 Antisense; Genasense®) Plus Gemtuzumab Ozogamcin (Mylotarg®) in Elderly Patients with Relapsed Acute Myeloid Leukemia (AML).

Joseph O. Moore, MD, Karen Seiter, MD, Jonathan E. Kolitz, MD, Wendy Stock, MD, Richard Yu, Stanley R. Frankel, MD

Blood (2004) 104 (11): 865.

https://doi.org/10.1182/blood.V104.11.865.865

Published: 2004

NARROW

Systematic Literature Review and Network Meta-Analysis of Treatments for Relapsed/Refractory Multiple Myeloma Patients

Social Network Analysis (SNA) of Salvage Therapies in Multiple Myeloma (MM)

Decitabine Is Effective In Patients with Myelodysplastic Syndromes Who Failed Prior Intensive Regimen: No Negative Impact of Prior Therapy

5-Year Follow-up of Patients with Relapsed/Refractory CLL Treated with Standard Chemotherapy with or without Oblimersen in Randomized Phase III Trial: Prognostic Factors and Predictive Factors for Treatment Effect

Oblimersen (OBL; Genasense®), a Phosphorothioate (PS) Bcl-2 Antisense Oliogonucleotide (ASO), Can Be Safely Administered by Bolus Subcutaneous (SC) Injection and Brief IV Infusion.

Addition of Oblimersen (Bcl-2 Antisense) to Fludarabine/Cyclophosphamide for Relapsed/Refractory Chronic Lymphocytic Leukemia Extends Survival in Patients Who Achieve CR/nPR: Results from a Randomized Phase 3 Study.

Waldenström macroglobulinemia

“Complete” Remission in Chronic Lymphocytic Leukemia (CLL) Is Strongly Affected by the Use of CT Scanning: Results from a Prospective Randomized Trial of Fludarabine Plus Cyclophosphamide (Flu/Cy) with or without Genasense (Oblimersen) in Patients with Relapsed or Refractory Disease.

Durable Clinical Benefit Is Associated with Objective Response and Not Lack of Progression in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Results from the Genasense/Flu/Cy Phase 3 Study.

Feasibility of Administering Oblimersen (G3139; Genasense) with Imatinib Mesylate in Patients with Imatinib Resistant Chronic Myeloid Leukemia (CML) - Cancer and Leukemia Group B Study 10107.

Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.

SPC2996 - A New Bcl-2 Inhibitor for the Treatment of CLL.

Pre-Clinical In Vitro Evaluation of BCL-2 Antisense Compound Genasense TM (G3139; Genta, Inc.) as a Targeted Pro-Apoptotic Agent for Leukemias with t(4;11)(q21;q23) Translocations.

siRNA Versus Antisense Locked Nucleic Acids: Stay Single!.

A Pilot Study of Genasense® (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.

Combined Targeting of the Proteasome and Bcl-2 Sensitizes Human B-Cell Lymphoma and Multiple Myeloma to Cyclophosphamide in In Vitro and In Vivo Models of These Diseases.

Phase II Trial of Oblimersen Sodium (G3139), Dexamethasone (Dex) and Thalidomide (Thal) in Relapsed Multiple Myeloma Patients (Pts).

A Phase I Trial of Oblimersen Sodium (G3139) for Relapsed or Refractory Waldenstrom Macroglobulinemia.

Phase 3 Randomized Trial of Fludarabine/Cyclophosphamide Chemotherapy with or without Oblimersen Sodium (Bcl-2 Antisense; Genasense; G3139) for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Phase 2 Study of Oblimersen Sodium (G3139; Bcl-2 Antisense; Genasense®) Plus Gemtuzumab Ozogamcin (Mylotarg®) in Elderly Patients with Relapsed Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only